{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:51:16Z","timestamp":1794711076987,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T00:00:00Z","timestamp":1489622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1245\/s10434-017-5839-x","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T12:48:19Z","timestamp":1489668499000},"page":"2319-2325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database"],"prefix":"10.1245","volume":"24","author":[{"given":"Mark","family":"Fairweather","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren K.","family":"Brais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Dutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.","family":"Kulke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,16]]},"reference":[{"issue":"18","key":"5839_CR1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063\u20133072.","journal-title":"J Clin Oncol."},{"issue":"4","key":"5839_CR2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","volume":"121","author":"J Hallet","year":"2015","unstructured":"Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589\u2013597.","journal-title":"Cancer."},{"issue":"4","key":"5839_CR3","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","volume":"97","author":"IM Modlin","year":"2003","unstructured":"Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934\u2013959.","journal-title":"Cancer."},{"issue":"9","key":"5839_CR4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/BF02557521","volume":"9","author":"QD Chu","year":"2002","unstructured":"Chu QD, Hill HC, Douglass HO Jr, et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol. 2002;9(9):855\u2013862.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"5839_CR5","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/01.sla.0000161981.58631.ab","volume":"241","author":"JG Touzios","year":"2005","unstructured":"Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241(5):776\u2013783","journal-title":"Ann Surg."},{"issue":"1","key":"5839_CR6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1072-7515(98)00099-4","volume":"187","author":"H Chen","year":"1998","unstructured":"Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998;187(1):88\u201392","journal-title":"J Am Coll Surg."},{"issue":"3","key":"5839_CR7","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1677\/ERC-09-0042","volume":"16","author":"A Ahmed","year":"2009","unstructured":"Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009;16(3):885\u2013894.","journal-title":"Endocr Relat Cancer."},{"issue":"12","key":"5839_CR8","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1245\/s10434-010-1154-5","volume":"17","author":"SC Mayo","year":"2010","unstructured":"Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17(12):3129\u20133136.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"5839_CR9","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s10620-006-9345-4","volume":"51","author":"TE Clancy","year":"2006","unstructured":"Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH. Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006;51(5):877\u2013884.","journal-title":"Dig Dis Sci."},{"issue":"282","key":"5839_CR10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"ELMP Kaplan","year":"1958","unstructured":"Kaplan EL MP. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457\u2013481.","journal-title":"J Am Stat Assoc."},{"issue":"1","key":"5839_CR11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","volume":"197","author":"JM Sarmiento","year":"2003","unstructured":"Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29\u201337.","journal-title":"J Am Coll Surg."},{"issue":"6","key":"5839_CR12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1477-2574.2010.00198.x","volume":"12","author":"ES Glazer","year":"2010","unstructured":"Glazer ES, Tseng JF, Al-Refaie W, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford). 2010;12(6):427\u2013433.","journal-title":"HPB (Oxford)."},{"issue":"1","key":"5839_CR13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/cncr.23523","volume":"113","author":"CS Cho","year":"2008","unstructured":"Cho CS, Labow DM, Tang L, et al. Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cancer. 2008;113(1):126\u2013134.","journal-title":"Cancer."},{"issue":"6","key":"5839_CR14","doi-asserted-by":"crossref","first-page":"724","DOI":"10.6004\/jnccn.2012.0075","volume":"10","author":"MH Kulke","year":"2012","unstructured":"Kulke MH, Benson AB 3rd, Bergsland E, et al. Neuroendocrine tumors. J Natl Compr Canc Netw. 2012;10(6):724\u2013764.","journal-title":"J Natl Compr Canc Netw."},{"issue":"6","key":"5839_CR15","first-page":"1091","volume":"108","author":"GP McEntee","year":"1990","unstructured":"McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108(6):1091\u20131096.","journal-title":"Surgery."},{"issue":"6","key":"5839_CR16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","volume":"39","author":"MH Kulke","year":"2010","unstructured":"Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39(6):735\u2013752.","journal-title":"Pancreas."},{"issue":"5","key":"5839_CR17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0002-9610(02)00998-4","volume":"184","author":"BM Burt","year":"2002","unstructured":"Burt BM, Brown K, Jarnagin W, DeMatteo R, Blumgart LH, Fong Y. An audit of results of a no-drainage practice policy after hepatectomy. Am J Surg. 2002;184(5):441\u2013445.","journal-title":"Am J Surg."},{"issue":"6","key":"5839_CR18","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.surg.2010.09.014","volume":"148","author":"HY Akyildiz","year":"2010","unstructured":"Akyildiz HY, Mitchell J, Milas M, Siperstein A, Berber E. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery. 2010;148(6):1288\u20131293","journal-title":"Surgery."},{"issue":"1","key":"5839_CR19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.surg.2007.01.036","volume":"142","author":"PJ Mazzaglia","year":"2007","unstructured":"Mazzaglia PJ, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery. 2007;142(1):10\u201319.","journal-title":"Surgery."},{"issue":"1","key":"5839_CR20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jso.20237","volume":"90","author":"D Elias","year":"2005","unstructured":"Elias D, Baton O, Sideris L, et al. Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. J Surg Oncol. 2005;90(1):36\u201342.","journal-title":"J Surg Oncol."},{"issue":"Suppl 1","key":"5839_CR21","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1007\/s12032-010-9750-6","volume":"28","author":"XD Dong","year":"2011","unstructured":"Dong XD, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol. 2011;28 Suppl 1:S286\u2013S290.","journal-title":"Med Oncol."},{"issue":"4","key":"5839_CR22","doi-asserted-by":"crossref","first-page":"302","DOI":"10.7326\/0003-4819-120-4-199402150-00008","volume":"120","author":"CG Moertel","year":"1994","unstructured":"Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med. 1994;120(4):302-309.","journal-title":"Ann Intern Med."},{"issue":"8","key":"5839_CR23","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.21389","volume":"104","author":"S Gupta","year":"2005","unstructured":"Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104(8):1590\u20131602.","journal-title":"Cancer."},{"issue":"6","key":"5839_CR24","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501\u2013513.","journal-title":"N Engl J Med."},{"issue":"6","key":"5839_CR25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514\u2013523.","journal-title":"N Engl J Med."},{"issue":"2","key":"5839_CR26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","volume":"117","author":"JR Strosberg","year":"2011","unstructured":"Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117(2):268\u2013275.","journal-title":"Cancer."},{"issue":"28","key":"5839_CR27","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656\u20134663.","journal-title":"J Clin Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-017-5839-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-017-5839-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-017-5839-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T11:43:14Z","timestamp":1498736594000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-017-5839-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,16]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["5839"],"URL":"https:\/\/doi.org\/10.1245\/s10434-017-5839-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,16]]}}}